Predictions
Jumia Technologies AG
Start price
Target price
Perf. (%)
€9.86
19.08.20
19.08.20
€6.00
04.11.21
04.11.21
54.16%
04.11.20
04.11.20
Good rating
Standard Investments for future growth
High valuation
Very low/no dividend yield expected
Fastly Inc.
Start price
Target price
Perf. (%)
€67.50
19.08.20
19.08.20
€69.00
04.11.21
04.11.21
-34.74%
01.11.21
01.11.21
EBIT growth >5% per year expected
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Rise Education Cayman Ltd
Start price
Target price
Perf. (%)
€5.70
19.08.20
19.08.20
€4.00
04.11.21
04.11.21
-91.05%
05.11.21
05.11.21
positive Cash Flow expected
EBIT decline/stagnation expected
High valuation
Very low/no dividend yield expected
Poseida Therapeutics Inc.
Start price
Target price
Perf. (%)
€7.62
19.08.20
19.08.20
-
20.08.20
20.08.20
1.44%
20.08.20
20.08.20
Monopar Therapeutics Inc.
Start price
Target price
Perf. (%)
€5.10
19.08.20
19.08.20
-
22.08.20
22.08.20
-7.06%
22.08.20
22.08.20
Rubius Therapeutics Inc.
Start price
Target price
Perf. (%)
€4.10
19.08.20
19.08.20
-
28.08.20
28.08.20
-2.93%
28.08.20
28.08.20
Youngevity International Inc.
Start price
Target price
Perf. (%)
€0.71
19.08.20
19.08.20
-
22.08.20
22.08.20
-4.26%
22.08.20
22.08.20
Odonate Therapeutics Inc.
Start price
Target price
Perf. (%)
€29.40
19.08.20
19.08.20
-
22.08.20
22.08.20
8.84%
22.08.20
22.08.20
Sensirion Holding AG
Start price
Target price
Perf. (%)
€30.40
19.08.20
19.08.20
€40.00
04.11.21
04.11.21
-
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Applied Therapeutics Inc
Start price
Target price
Perf. (%)
€22.00
18.08.20
18.08.20
-
22.08.20
22.08.20
-10.91%
22.08.20
22.08.20
Revive Therapeutics Ltd.
Start price
Target price
Perf. (%)
€0.19
18.08.20
18.08.20
-
25.08.20
25.08.20
-2.16%
25.08.20
25.08.20
Co-diagnostics Inc.
Start price
Target price
Perf. (%)
€12.90
18.08.20
18.08.20
-
19.08.20
19.08.20
-4.65%
19.08.20
19.08.20
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group